The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
@Philsy027
Thanks. I assume your number is pre-tax.
Looking in the accounts I see there are convertible loan notes for 60 million shares at 19p. This goes back to 2019. I do not see any eventuality other than conversion.
But doesn't half have to go to CalEnergy?
With volumes in mmscf/d converted into therms (divide by 96) and then converted into MW (divide by 34) to get volume by price (say Euro 210 per MW). Exchange rate Euro 1.20 to GBP. 50 mmscf/d should give over £2.5million per day after deducting costs of production. After tax at 65% profits in excess of £800K per day. Have I got this right or should I retake my Maths GSCE?
What will be interesting in the half year update is the guidance for the rest of the year. Dividends will have to wait for publication of FY results next year.
The marketcap peaked in 2019 at around £360m when there were 180m shares in issue. There are now nearly 350m shares in issue. 80p a share might be achievable if all goes well.
"May be required to indemnify GSK or Pfizer". Bizarre but surely most unlikely.
AGL and STX are not the same. Cancer is a much bigger market than iron deficiency. AN will see this through to the exit.
Well it's 80p this time. Disgraceful.
Apologies for posting incorrect information re the last placing. Look forward to announcement at 7am.
Hopefully it will be at a better price than the last one which was at 80p. Regret not selling more on FDA approval announcement.
Those are that not yet in.
The wording suggests that there is no need for financing. Some institutions will not be pleased.
Sorry but this is normal. Look what happened to STX and FUM when they got their respective approvals. A big jump and then a slow decline until the next bit of news. Not enough institutional shareholders.
And with the exchange rate at 1.226, US$ 1 million is £815K. At year-end 2021 the rate was US$ 1.35 ish (£740k). It has dropped off a cliff since April. It would be interesting to know how much of their expenses are in US$.
These have been reported in every year's financial statements since 2014. They are deferred in the event of liquidation but it doesn't specify their rights in the event of takeover or dividends. Furthermore the number was not subject to consolidation as the ordinary shares were two years ago.
Agreed but usually they are obliged to keep sealed lips. Another case where the FD/CFO left while we all being told to hold on to our golden tickets was Sound Energy in the spring of 2017. I suspect there was a culture clash but it didn't look good.
No, talking but action please. Hopefully the accounts will reflect the transformation brought about by Wressle, will result in a proposal to reduce the share premium account, and then, if the share price continues to undevalue the company, allow the company to commence a buyback programme.